FISHER & PAYKEL HEALTHCARE C

Fisher & Paykel’s upcoming half‑year results reveal robust margins, smart‑device growth and how reimbursement shifts in the U.S. and EU affect future returns.

Kingfish Limited’s latest NAV drops to $1.24, with Fisher & Paykel Healthcare at 20% of holdings. Expect FP’s half‑year results on 26 Nov 2026 and a webcast discussion.

Fisher & Paykel Healthcare sells 13 hectares to fund a new South Auckland hospital, boosting community care while keeping space for future medical‑tech growth.

Kingfish Limited reports a slight NAV drop to $1.2608, narrowing its discount and spotlighting Fisher & Paykel as the top holding for growth and dividends.

Kingfish Limited’s latest NAV update shows a tighter 8 % price‑to‑NAV spread and a modest NAV dip, driven by concentrated NZ holdings, treasury‑stock moves and performance fees—key insights for investors navigating regulatory risk and dividend growt…